© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
March 03, 2021
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Shaakir Hasan, DO, discusses socioeconomic characteristics associated with the diagnosis and management of bladder cancer.
March 01, 2021
The subgroup analysis assessed data from the pivotal phase 3 JAVELIN Bladder 100 trial showed.
February 26, 2021
“[Urologists are] very comfortable giving agents in the bladder, so [CG0070] really fits in line with what we give,” says investigator Edward Uchio, MD.
February 25, 2021
Based on these findings, an application has been filed with the FDA to expand enfortumab vedotin’s approval to include cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor.
February 23, 2021
Boorjian anticipates research with nadofaragene firadenovec in settings beyond BCG-unresponsive non-muscle invasive bladder cancer.
"Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages," says urologist Scott P. Campbell, MD.
February 22, 2021
The withdrawal comes after the confirmatory phase 3 DANUBE trial missed its primary end points.
February 19, 2021
Adjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.
Determining grade of disease is important, as nephron-sparing approaches may be feasible.